ADMA Biologics Securities Class Action
Analysis based on 7 articles · First reported Aug 03, 2026 · Last updated Aug 07, 2026
The lawsuit could negatively affect ADMA Biologics' stock price and investor confidence, as allegations of channel stuffing and inadequate internal controls raise concerns about revenue quality and governance. The outcome may lead to financial penalties or settlements, impacting the company's balance sheet and reputation.
A securities class action lawsuit has been filed against ADMA Biologics, Inc. and certain of its executives, alleging violations of federal securities laws. The complaint, Mazzarino v. ADMA Biologics, Inc., et al., No. 26-cv-04793, is pending in the United States — United States District Court for the District of New Jersey. The class period covers purchases of ADMA securities between August 9, 2024 and March 25, 2026. The plaintiffs allege that the company made false and misleading statements and omissions, including engaging in an undisclosed related party transaction, using channel stuffing to inflate revenue, and lacking adequate internal controls. Kahn Swick & Foti, LLC (KSF) is notifying investors of the deadline to apply for lead plaintiff, which is August 10, 2026. The lawsuit seeks to recover losses for investors who purchased ADMA securities during the class period.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard